The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis

Carcinogenesis

Volumn 34, Issue 2, 2013, Pages 268-276

  Casalà, Carla ^a   Gil Guiñón, Estel ^a   Ordóñez, José Luis ^b   Miguel Queralt, Solange ^a   Rodríguez, Eva ^a   Galván, Patricia ^a   Lavarino, Cinzia ^a   Munell, Francina ^c   de Alava, Enrique ^b,d   Mora, Jaume ^a   De Torres, Carmen ^a  

^a HOSPITAL SANT JOAN DE DÉU   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM SENSING RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 3; PARATHYROID HORMONE RELATED PROTEIN; PERIPHERAL MYELIN PROTEIN 22; TRICHOSTATIN A;

3' UNTRANSLATED REGION; ADULT; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CHROMOSOME 3; CONTROLLED STUDY; CPG ISLAND; DNA BASE COMPOSITION; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GANGLIONEUROMA; GENE SILENCING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MONOSOMY; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; SECOND LOOK SURGERY;

ADRENAL GLANDS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MONOSOMY; NEOPLASM STAGING; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CALCIUM-SENSING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873558759     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs338     Document Type: Article

References (46)

1. Maris,J.M. (2010) Recent advances in neuroblastoma. N. Engl. J. Med., 362, 2202-2211.
2. Brodeur,G.M. (2003) Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer, 3, 203-216.
3. Ambros,I.M. et al. (1996) Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma. N. Engl. J. Med., 334, 1505-1511.
4. Bown,N. et al. (1999) Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N. Engl. J. Med., 340, 1954-1961.
5. Brodeur,G.M. et al. (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science, 224, 1121-1124.
6. Cohn,S.L. et al. (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J. Clin. Oncol., 27, 289-297.
7. Mora,J. et al. (2007) Comprehensive analysis of tumoral DNA content reveals clonal ploidy heterogeneity as a marker with prognostic significance in locoregional neuroblastoma. Genes. Chromosomes Cancer, 46, 385-396.
8. Ross,R.A. et al. (1995) Human neuroblastoma I-type cells are malignant neural crest stem cells. Cell Growth Differ., 6, 449-456.
9. Walton,J.D. et al. (2004) Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia, 6, 838-845.
10. Shimada,H. et al. (2001) International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer, 92, 2451-2461.
11. Henrich,K.O. et al. (2011) CAMTA1, a 1p36 tumor suppressor candidate, inhibits growth and activates differentiation programs in neuroblastoma cells. Cancer Res., 71, 3142-3151.
12. Liu,Z. et al. (2011) CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression. Cell Death Differ., 18, 1174-1183.
13. Takenobu,H. et al. (2011) CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene, 30, 97-105.
14. de Torres,C. et al. (2009) The calcium-sensing receptor and parathyroid hormone-related protein are expressed in differentiated, favorable neuroblastic tumors. Cancer, 115, 2792-2803.
15. Brown,E.M. et al. (1993) Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature, 366, 575-580.
16. Saidak,Z. et al. (2009) The role of the calcium-sensing receptor in the development and progression of cancer. Endocr. Rev., 30, 178-195.
17. Liao,J. et al. (2006) Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res., 66, 9065-9073.
18. Haven,C.J. et al. (2004) Differential expression of the calcium sensing receptor and combined loss of chromosomes 1q and 11q in parathyroid carcinoma. J. Pathol., 202, 86-94.
19. Chakrabarty,S. et al. (2003) Extracellular calcium and calcium sensing receptor function in human colon carcinomas: promotion of E-cadherin expression and suppression of beta-catenin/TCF activation. Cancer Res., 63, 67-71.
20. Canaff,L. et al. (2002) Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J. Biol. Chem., 277, 30337-30350.
21. DePreter,K. et al. (2002) Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay. Mod. Pathol., 15, 159-166.
22. Brandes,J.C. et al. (2007) Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter. Oncogene, 26, 6229-6237.
23. Lavarino,C. et al. (2008) Differential expression of genes mapping to recurrently abnormal chromosomal regions characterize neuroblastic tumours with distinct ploidy status. BMC Med. Genomics, 1, 36.
24. Becker,J. et al. (2006) Keratoepithelin suppresses the progression of experimental human neuroblastomas. Cancer Res., 66, 5314-5321.
25. Alaminos,M. et al. (2005) EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Res., 65, 2565-2571.
26. Kaplan,E.L. et al. (1958) Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53, 457-481.
27. Mantel,N. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 50, 163-170.
28. Cox,D.R. (1972) Regression models and lifetables. J. R. Stat. Soc. B, 74,187-220.
29. Alaminos,M. et al. (2004) Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J. Natl. Cancer Inst., 96, 1208-1219.
30. Yang,Q. et al. (2004) Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin. Cancer Res., 10, 8493-8500.
31. Abe,M. et al. (2005) CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res., 65, 828-834.
32. Yang,Q. et al. (2007) Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin. Cancer Res., 13, 3191-3197.
33. Hizaki,K. et al. (2011) Epigenetic inactivation of calcium-sensing receptor in colorectal carcinogenesis. Mod. Pathol., 24, 876-884.
34. Yadav,A.K. et al. (2009) Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas. JAMA, 302, 276-289.
35. Spitz,R. et al. (2006) Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes. Chromosomes Cancer, 45, 1130-1142.
36. Dannenberg,H. et al. (2000) Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas. Am. J. Pathol., 157, 353-359.
37. Onken,M.D. et al. (2007) Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clin. Cancer Res., 13, 2923-2927.
38. Ye,C.J. et al. (2009) Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. J. Cell. Physiol., 219, 288-300.
39. Yano,S. et al. (2000) Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int., 58, 1980-1986.
40. Ho,C. et al. (1995) A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat. Genet., 11, 389-394.
41. Hjälm,G. et al. (2001) Filamin-A binds to the carboxyl-terminal tail of the calcium-sensing receptor, an interaction that participates in CaRmediated activation of mitogen-activated protein kinase. J. Biol. Chem., 276, 34880-34887.
42. Loretz,C.A. et al. (2004) cDNA cloning and functional expression of a Ca2+-sensing receptor with truncated C-terminal tail from the Mozambique tilapia (Oreochromis mossambicus). J. Biol. Chem., 279, 53288-53297.
43. Zhang,M. et al. (2005) High affinity interaction with filamin A protects against calcium-sensing receptor degradation. J. Biol. Chem., 280, 11140-11146.
44. DeCarvalho,D.D. et al. (2012) DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell, 21, 655-667.
45. Meloche,S. et al. (2007) The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene, 26, 3227-3239.
46. Cagnol,S. et al. (2010) ERK and cell death: mechanisms of ERK-induced cell death-apoptosis, autophagy and senescence. FEBS J., 277, 2-21.